Clinical and Molecular Hepatology

"Primary prevention"

Aspirin for hepatocellular carcinoma prevention in MASLD: How far are we ready to proceed?: Editorial on “Aspirin and HCC risk in MASLD: Nationwide cohort study with genetic risk analysis”: Yang-Hyun Baek; Clin Mol Hepatol 2026;32(3):1429-1432.
Published online January 9, 2026; DOI: https://doi.org/10.3350/cmh.2025.1482

Citations

Citations to this article as recorded by

Correspondence to editorial 1 on “Aspirin and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease: nationwide cohort study with genetic risk analysis”
Moon Haeng Hur, Hyunjae Shin, Yoon Jun Kim
Clinical and Molecular Hepatology.2026; 32(3): e378. CrossRef
Reply to correspondence on “Aspirin and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease: nationwide cohort study with genetic risk analysis”
Yang-Hyun Baek
Clinical and Molecular Hepatology.2026; 32(3): e439. CrossRef

Snapshot

Examining the therapeutic landscape of beta-blockers in portal hypertension: Anna Brujats, Càndid Villanueva; Clin Mol Hepatol 2024;30(4):1055-1059.
Published online March 6, 2024; DOI: https://doi.org/10.3350/cmh.2024.0144

Citations

Citations to this article as recorded by

Decreasing systemic inflammation after TIPS: Still hope for the liver: Reply to correspondence on “Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrh
Georg Semmler, Lorenz Balcar, Mattias Mandorfer
Clinical and Molecular Hepatology.2025; 31(2): e224. CrossRef
Principles of Non-selective Beta-blocker Usage for Cirrhosis-associated Complications
Daisy K. Maclaine, Kosha J. Mehta
SN Comprehensive Clinical Medicine.2025;[Epub] CrossRef
Treating onychomycosis in diabetic patients: risk, therapy, and topical opportunity
Aditya K. Gupta, Amanda Liddy, Tong Wang, Su Yong Choi, Elizabeth A. Cooper
Journal of Dermatological Treatment.2025;[Epub] CrossRef